Additional benefits would be seen for extended life expectancy from birth

Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis

Potential disparities in uptake seen by socioeconomic status and locality among privately insured adults

Carotid plaque burden and coronary artery calcium score both significantly linked to all-cause mortality in asymptomatic individuals

Better remission and response seen with bright light therapy before four weeks and after four weeks

Ovarian cancer detected with specificity >99 percent and sensitivity ranging from 69 to 100 percent depending on stage

Fear also tied to worse mental and physical health

17.4 percent in GLP-1 RA group undergoing esophagogastroduodenoscopies had food retention versus none in the control group

Regardless of one or two doses, mpox antibodies wane by six to 12 months

In addition, genetic test may assist in identifying patients more likely to respond